Brings more than 20 years of clinical development and oncology leadership
Solna, Sweden, 11 April 2022 – Vivesto AB, an oncology-focused specialty pharmaceutical company, today announces the appointment of Dr. Daniel Tesfa as Chief Medical Officer (CMO), who will be responsible for leading the clinical development of all Vivesto’s oncology programmes in concert with our CSO, Dr. Reinhard Koenig, responsible for all pre-clinical activities. Dr. Tesfa, who will join Vivesto no later than 1 July, will report to CEO Francois Martelet and will also join Vivesto’s Management team.
Dr. Tesfa brings extensive experience in clinical development and precision oncology over 20 years. Most recently, from 2020, he served as Medical Director, Clinical and Translation Science Hematology at listed Swedish biopharmaceutical company SOBI (Swedish Orphan Biovitrum AB), where he led clinical development.
Prior to his time at SOBI, from 2018 until 2020, Dr. Tesfa worked as Head of Oncology and Hematology at Bayer, Scandinavia, where he was a Medical Advisor and manager for the medical team.
Other prior roles include Country Medical Manager Oncology and Hematology, at Roche, Sweden, where he acted as a Medical Advisor and had a leading role in launching the hemophilia and lymphoma products, and also worked on treatments for colorectal, breast and lung cancers. Dr. Tesfa also brings first-hand experience as a specialist doctor as he was Head of Polyclinical Section at the former Hematology Center Karolinska Huddinge.
Dr. Tesfa holds a PhD in Medicine from Karolinska Institutet and an M.D. from the University of Lund, Sweden. He is also a fellow of Swedish Society of Medicine, and a member of the Swedish Hematology and Oncology Association.
François Martelet, M.D., CEO, commented: “We are delighted to welcome Daniel to the Vivesto team. His extensive and first-hand experience working in clinical development and oncology makes him a perfect fit for Vivesto going forward, as we extend our internal capabilities for the development of solutions for hard-to-treat and late-stage cancers.”
Dr. Daniel Tesfa, CMO, said: “I am looking forward to joining Vivesto and helping to deliver the mission to improve survival and quality of life for patients with cancer, as the company progresses its pipeline of exciting clinical stage development programmes.”
For More Information:
Francois Martelet, Chief Executive Officer
Phone: +46 18-50 54 40
Consilium Strategic Communications
Jonathan Birt, Ashley Tapp
Phone: +44 (0)20 3709 5700
Vivesto is a specialty pharmaceutical company focused on the development of new therapeutic options for patients suffering from hard-to-treat cancers. It has a growing pipeline of clinical-stage assets targeting late-stage cancers. Apealea® (paclitaxel micellar) is being made available to ovarian cancer patients through a partnership with Elevar Therapeutics, Inc. Development programs include Cantrixil, in clinical development for late-stage ovarian cancer, and docetaxel micellar, in development for advanced prostate cancer. Vivesto has proprietary drug delivery technology designed to improve solubility, efficacy and safety. Vivesto’s shares are traded on Nasdaq Stockholm (VIVE). To find out more about Vivesto please visit www.vivesto.com.